Telix Pharmaceuticals Limited (TLX)
NASDAQ: TLX · Real-Time Price · USD
9.71
-0.17 (-1.72%)
At close: Nov 7, 2025, 4:00 PM EST
9.70
-0.01 (-0.10%)
After-hours: Nov 7, 2025, 4:10 PM EST
Telix Pharmaceuticals Revenue
Telix Pharmaceuticals had revenue of $390.36M in the half year ending June 30, 2025, with 165.59% growth. This brings the company's revenue in the last twelve months to $664.23M, up 55.35% year-over-year. In the year 2024, Telix Pharmaceuticals had annual revenue of $484.69M with 41.49% growth.
Revenue (ttm)
$664.23M
Revenue Growth
+55.35%
P/S Ratio
4.95
Revenue / Employee
$1,570,273
Employees
423
Market Cap
3.29B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 484.69M | 142.12M | 41.49% |
| Dec 31, 2023 | 342.57M | 233.76M | 214.82% |
| Dec 31, 2022 | 108.81M | 103.29M | 1,870.12% |
| Dec 31, 2021 | 5.52M | 1.50M | 37.33% |
| Dec 31, 2020 | 4.02M | 1.57M | 64.26% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
TLX News
- 4 days ago - Telix to Participate in UBS and Jefferies Global Healthcare Conferences - GlobeNewsWire
- 16 days ago - Telix Pharmaceuticals Limited Investigated by the Portnoy Law Firm - GlobeNewsWire
- 17 days ago - Telix Doses First Patient in SOLACE Trial for Metastatic Bone Pain - GlobeNewsWire
- 24 days ago - TELIX INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Reminds Telix Pharmaceuticals Investors to Contact the Firm Regarding Ongoing Investigation on Behalf of Stockholders - GlobeNewsWire
- 25 days ago - Telix Pharmaceuticals Enters Q4 On Strong Footing With Stabilized Pricing Pressures, Upgraded Annual Sales Guidance - Benzinga
- 26 days ago - Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded - GlobeNewsWire
- 6 weeks ago - CMS Grants Transitional Pass-Through Status for Gozellix - GlobeNewsWire
- 7 weeks ago - Telix Pharmaceuticals Limited (TLX) Hits Another Roadblock After SEC Subpoena, Shares Fall Again -- Hagens Berman - GlobeNewsWire